Protein expression and antifungal effect of fluconazole-resistant Candida species following effective in vitro treatment with K21, a novel antifungal agent
Philosophiae Doctor - PhD === Background: Oropharyngeal candidiasis, caused by the fungus Candida, is the most common opportunistic infection affecting the quality of life of immunocompromised patients. Fluconazole is widely used as the first line of treatment for fungal infections. However, the i...
Main Author: | John, Cathy Nisha |
---|---|
Other Authors: | Africa, Charlene WJ |
Language: | en |
Published: |
University of Western Cape
2021
|
Subjects: | |
Online Access: | http://hdl.handle.net/11394/7889 |
Similar Items
-
K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-Associated Candida Species
by: Cathy N. John, et al.
Published: (2019-05-01) -
In vitro antifungal activities of Euphorbia macroclada and fluconazole against pathogenic Candida species
by: Shahram Mahmoudi, et al.
Published: (2015-03-01) -
Surveillance of antifungal susceptibilities in clinical isolates of Candida species at 36 hospitals in China from 2009 to 2013
by: Lei Zhang, et al.
Published: (2015-04-01) -
Antifungal Activity of Minocycline and Azoles Against Fluconazole-Resistant Candida Species
by: Jingwen Tan, et al.
Published: (2021-05-01) -
In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and -resistant strains of Candida dubliniensis
by: Liliane Alves Scheid, et al.